In yesterday’s Wall Street session, Adial Pharmaceuticals Inc. (NASDAQ:ADIL) shares traded at $0.33, down -15.32% from the previous session.
As of this writing, 2 analysts cover Adial Pharmaceuticals Inc. (NASDAQ:ADIL). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $6.00 and a low of $6.00, we find $6.00. Given the previous closing price of $0.38, this indicates a potential upside of 1478.95 percent. ADIL stock price is now 18.54% away from the 50-day moving average and 2.34% away from the 200-day moving average. The market capitalization of the company currently stands at $9.42M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
There are 0 analysts who have given it a hold rating, whereas 2 have given it a buy rating. Brokers who have rated the stock have averaged $6.00 as their price target over the next twelve months.
With the price target of $5, Maxim Group recently initiated with Buy rating for Adial Pharmaceuticals Inc. (NASDAQ: ADIL).
Insiders disposed of 166,667 shares of company stock worth roughly $55000.11 over the past 1 year. A total of 4.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ADIL stock. A new stake in Adial Pharmaceuticals Inc. shares was purchased by MANCHESTER CAPITAL MANAGEMENT LLC during the first quarter worth $392,000. ENVESTNET ASSET MANAGEMENT INC invested $4,000 in shares of ADIL during the first quarter. In the first quarter, AMERICAN PORTFOLIOS ADVISORS acquired a new stake in Adial Pharmaceuticals Inc. valued at approximately $2,000. In total, there are 26 active investors with 7.20% ownership of the company’s stock.
Wednesday morning saw Adial Pharmaceuticals Inc. (NASDAQ: ADIL) opened at $0.3651. During the past 12 months, Adial Pharmaceuticals Inc. has had a low of $0.20 and a high of $2.08. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 1.60, and a quick ratio of 1.60. The fifty day moving average price for ADIL is $0.2748 and a two-hundred day moving average price translates $0.3187 for the stock.
The latest earnings results from Adial Pharmaceuticals Inc. (NASDAQ: ADIL) was released for Mar, 2023.
Adial Pharmaceuticals Inc.(ADIL) Company Profile
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.
